Approval · Notice of Compliance 26126 · 2021
CIPRO: Notice of Compliance 26126
Issued June 21, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26126
- Date
- June 21, 2021
- Company
- Bayer Inc.Elkhart, Indiana, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- To update the CIPRO/CIPRO ORAL SUSPENSION Product Monograph (PM), including expanding the hypersensitivity contraindications, adjusting the timing of taking a missed dose, and migrating the PM to the 2020 format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CIPRO | Not yet assigned | — |
| CIPRO ORAL SUSPENSION | Not yet assigned | — |
Medicinal ingredients
- CIPROFLOXACIN HYDROCHLORIDE 500 MG per TAB
- CIPROFLOXACIN HYDROCHLORIDE 10 G per 100ML